Related Experiment Videos
Actions of leukaemia inhibitory factor on megakaryocyte and platelet formation
D Metcalf1, P Waring, N A Nicola
1Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Victoria, Australia.
Abstract:
Leukaemia inhibitory factor (LIF) is able to potentiate megakaryocyte colony formation in cultures of mouse bone marrow cells in the presence of multi-CSF (interleukin 3). Membrane receptors for LIF are present on mouse megakaryocytes and receptor numbers increase with increasing maturation of the cells. When injected into normal mice at doses of 0.2-2 micrograms two to three times daily, LIF induced a rise in platelet numbers, which reached up to twice normal values during the second week of injections. This rise was preceded by a rise first in megakaryocyte progenitor numbers, then in mature megakaryocytes in the bone marrow and spleen. Injections of LIF also marginally accelerated platelet regeneration in mice pre-injected with 5-fluorouracil or subjected to whole-body irradiation and transplantation of marrow cells. In view of similar responses to LIF in parallel studies in primates, clinical trial of LIF in patients with thrombocytopenia is warranted.
Insights
Leukaemia inhibitory factor (LIF) boosts platelet production by increasing megakaryocyte numbers in mice. LIF administration shows potential for treating thrombocytopenia, warranting clinical trials.
Area of Science:
- Hematology
- Cell Biology
- Biotechnology
Background:
- Leukaemia inhibitory factor (LIF) is a cytokine known to influence cell growth and differentiation.
- Megakaryocytes are essential for platelet production, a critical component of hemostasis.
Purpose of the Study:
- To investigate the effect of Leukaemia inhibitory factor (LIF) on megakaryocyte colony formation and platelet production in vivo.
- To evaluate the therapeutic potential of LIF in models of thrombocytopenia.
Main Methods:
- Bone marrow cell cultures were used to assess megakaryocyte colony formation in the presence of LIF and multi-CSF (interleukin 3).
- LIF was administered to normal mice, and platelet counts, megakaryocyte progenitor numbers, and mature megakaryocytes in bone marrow and spleen were monitored.
- Platelet regeneration was assessed in mice treated with 5-fluorouracil or subjected to irradiation and bone marrow transplantation.
Main Results:
- LIF potentiated megakaryocyte colony formation in vitro.
- In vivo, LIF injections increased platelet counts up to twofold normal values within two weeks.
- LIF administration led to an initial increase in megakaryocyte progenitors, followed by an increase in mature megakaryocytes in bone marrow and spleen.
- LIF marginally accelerated platelet regeneration in mice with induced thrombocytopenia.
Conclusions:
- Leukaemia inhibitory factor (LIF) effectively stimulates megakaryopoiesis and thrombopoiesis in mice.
- The findings support the potential of LIF as a therapeutic agent for thrombocytopenia.
- Further clinical investigation of LIF for treating thrombocytopenia in humans is warranted based on these preclinical results and parallel primate studies.